Ashfield unites its businesses under the Ashfield Commercial & Medical Services banner
News on Johnson & Johnson, Novartis and Merck
News on Aegerion, Vivus, Merck and Gilead
The new network, PD One, will allow reps to connect with HCPs through PDI's Medical Bag.
Gilead will not add any more sales reps to Sovaldi despite the unanticipated indication it grabbed for genotype-1 patients
News on Araid Pharma, Bristol-Myers Squibb, Forest Labs and Eisai
Two months after it was pulled from the US market, Iclusig is returning with a narrower approval.
Pew Charitable Trust's proposed conflict of interest guidelines could mean even less face time for sales reps and less industry money for CME programs.
Although doctors still like sales reps, Capgemini and Quantia's researchers find their appeal is on the decline, while digital is on the rise. While age is a factor, it's the workplace that's shaping physician preferences.
News on Eisai, Vivus and Amarin
Although doors are increasingly closing on reps, data from CMI/Compas show a number of contradictions among healthcare practitioners and what they want when it comes to pharma industry communications.
Despite attempts to boost the market profile of Belviq, partners Arena and Eisai appear to be facing the same woes as their prescription-obesity treatment peer Vivus: disappointing sales.
News on Merck, Pfizer and United Drug Plc
The drug company is ceasing US distribution and marketing the leukemia drug after the FDA said it was worried about blood clots among clinical trial patients.
The company says it is moving its Januvia sales pitch from defending market share to expanding it.
Valeant sales reps started doing something different in August. In addition to talking to dermatologists about prescription medications, they started dropping off samples of the drug maker's OTC medication AcneFree
Bob Harrell, IMS Health-Appature's director of marketing says its cloud-based system Journeys, which launched in August, shows how customers are behaving in real time
News on Mission Pharmacal, Lundbeck and Boehringer Ingelheim
Education around the Sunshine Act has been ongoing, and a number of organizations are seeking to help physicians stay up-to-speed with the requirements
A study by consulting research firm ZS Associates shows the wedge between oncologists and sales reps has gotten so large that oncology is the most restrictive specialty for the second year in a row
News on Vivus, Bristol-Myers Squibb and GlaxoSmithKline
Mobile isn't just the new normal but a platform where doctors connect with—and remember—ads, according to a study by communications firm CMI/Compas
The American Medical Association's June decision to label obesity as a disease could represent a significant marketing opportunity for the prescription weight-loss category
News on Duchesnay, Eli Lilly and Sigma Tau
The Justice Department has accused Novartis' US unit of offering opulent dinners and paying physicians as an enticement to prescribe its drugs.
A prescription morning sickness drug combining doxylamine succinate and pyridoxine hydrochloride is returning to US pharmacies after a 30-year absence.
News on Pfizer, Amgen, Eli Lilly and Merck
A recent study by Booz & Co, signals what it takes to convert emerging markets from potential revenue sources into financially sustaining markets
Sales jobs aren't vaporizing, Accenture's global director of life sciences Craig Roberston told MM&M—rather, they're being reconfigured, and in some cases, relocated.
News on Bristol-Myers Squibb, AstraZeneca and Accenture
A panel at the New York ePharma Summit discussed the split between doctors' needs and pharma's agenda
A study finds that many medical students and residents feel confident that they can accept gifts from the pharmaceutical industry and remain unbiased—although they aren't so sure about their peers.
News on Mylan, Royalty Pharma and Roche
Drug maker Santarus is bringing on 85 reps ahead of the launch of its ulcerative colitis drug Uceris.
Physician trust in pharmaceutical brands is driven by an emotional connection as well as functional attributes and perceptions of the manufacturer, said Harris Interactive
News on FDA, Pfizer and PhRMA
The doctors who said in 2012 that drug company-sponsored lunches couldn't sway their prescribing are being undercut by a study published in JAMA's Internal Medicine.
The warfarin-replacement market has been bracing for the entry of Eliquis since well before the drug won FDA approval in December
News on IMS Health, Televox, the American Academy of Nurse Practitioners and the American College of Nurse Practitioners
Breakfast may be called the most important meal of the day, but MedScape's 2012 Ethics Survey results show that lunch also weighs on doctors' minds.
Companies can improve their performance by blending hard numbers, like outcomes and cost savings, with softer messaging that centers on payer and patient relationships, a PricewaterhouseCoopers report argues.
News on GolinHarris, McKesson and Shire
Although Vivus weight loss drug Qsymia is getting a cold reception from regulators in the EU, where it is known as Qsvia, the company said the US sales push for the drug is building.
Sales of Amgen's Prolia are set to rise after a "soft" quarter, thanks to a sales force overhaul and an impending return to TV advertising, the company said in a third quarter results call.
News on Eli Lilly, Novartis, Johnson & Johnson and Pfizer
The swirl of paper surrounding KV Pharmaceuticals' request for Chapter 11 bankruptcy protection continues to grow. At the center of the proceedings is the controversy surrounding Makena
Horizon Pharmaceuticals announced in October that it has added 70 reps to its sales force as part of the Deerfield, Ill., company's push to promote both its RA drug Duexis and Rayos (prednisone).
News on Targacept, Bristol-Myers Squibb and Merck
The drug industry may be shifting its attention to specialty drugs, but data shows that detailing pressure and pharmaceutical rep access are still much higher in primary care.
Pharmacists are the latest recruits in the government's push to reduce the nation's risk of heart disease.